Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
STAMFORD, Conn., Oct. 31, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced the presentation of a late-breaking CR845 poster at the American College of Rheumatology ACR/ARHP Annual Meeting, to be held November 3-8, 2017 in San Diego.
The poster presentation will include clinical trial data from the Company’s completed Phase 2b study of Oral CR845 in patients with osteoarthritis of the hip or knee. CR845 is Cara’s first-in-class, peripherally selective kappa opioid receptor agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.
Details for the presentation are as follows:
CR845 Poster Presentation:
| Title: | "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee” |
| Presentation Number: | 15L |
| Date / Time: | Tuesday, November 7, 2017; 9:00 – 11:00 a.m. PT |
| Presenter: | Sukirti Bagal, M.D., M.P.H., Senior Medical Director, Cara Therapeutics |
For information about the ACR/ARHP Annual Meeting, visit https://www.rheumatology.org/Annual-Meeting.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
[email protected]
